Informed Consent for Genetic Research, Genomic Sequencing, and Biospecimen Banking

Section 1info grid
Section 2text block
Section 3text block
Section 4list block
Section 5text block
Section 6text block
Section 7list block
Section 8text block
Section 9text block
Section 10text block
Section 11list block
Section 12text block
Section 13signature block

Informed Consent for Genetic Research, Genomic Sequencing, and Biospecimen Banking

Study, Site, and Participant Information

Voluntary Nature of Participation

Your participation in this genetic research study and the donation of your biological specimens is entirely voluntary. You may choose not to participate. If you agree to participate, you may withdraw your consent at any time without penalty or loss of any medical benefits to which you are otherwise entitled. Your decision will not affect your current or future medical care at this institution. Withdrawing from the study does not recall or delete data or specimens that have already been de-identified, distributed, or analyzed in scientific publications.

Purpose and Scientific Background

You are being invited to participate in a genomic research registry and biobank. Genetic research aims to understand how changes in human DNA (the hereditary code inside cells) affect health and disease. By analyzing genetic material (DNA and RNA) from thousands of individuals, researchers study genetic variations that correlate with specific cardiovascular, oncological, neurological, or metabolic disorders. This study will perform advanced genomic sequencing (such as whole-exome or whole-genome sequencing) to map your genetic profile and correlate it with de-identified clinical history.

Biospecimen Collection and Processing Procedures

Specimen Acquisition: The study team will collect a biological sample from you. This will consist of a standard blood draw (approximately 10 mL to 20 mL of whole blood from a vein in your arm), a saliva sample, or a buccal swab (swabbing the inside of your cheek), depending on the protocol requirements.
DNA and RNA Isolation: Specialized laboratory scientists will extract and isolate genetic material (DNA and RNA) from your biological specimen.
Genomic Analysis: Extracted genetic material will be analyzed using next-generation sequencing technologies. This includes sequencing specific target genes, all protein-coding genes (whole-exome sequencing), or your entire genomic sequence (whole-genome sequencing).
Biobanking: Leftover specimens, genomic sequence files, and related clinical datasets will be stored in secure, temperature-controlled repositories (biobanks) for future, unspecified biomedical research.

Federal Genetic Privacy Protections (GINA)

A federal law called the Genetic Information Nondiscrimination Act (GINA) provides legal protections against genetic discrimination. GINA makes it illegal for health insurance companies, group health plans, and employers with 15 or more employees to write policies or make employment decisions based on your genetic information (such as predisposition to a disease or genomic sequencing results). However, GINA does not apply to life insurance, disability insurance, or long-term care insurance providers, who may request genetic information before issuing policies. The research team will maintain strict electronic separation between your clinical records and genetic data to mitigate this risk.

Mandatory Commercialization and IP Disclosure

Your biological specimens, cell lines, and de-identified genomic data may contribute to the development of new diagnostic tests, diagnostic algorithms, or medical therapies that hold commercial value. Under federal Common Rule guidelines (45 CFR 46.116(c)(9)), you are informed that these materials may be used for commercial profit by the sponsor, research institution, or external biopharma partners. You will not receive any financial compensation, royalties, or proprietary rights from any commercial discoveries or profits derived from your specimens.

Foreseeable Risks and Privacy Disclosures

Physical Risks: For blood draws, risks include transient local pain, bruising, lightheadedness, bleeding, hematoma, or rarely, a local skin infection at the needle insertion site.
Privacy and Re-identification Risks: Your genetic sequence is unique to you. Despite advanced de-identification protocols (such as stripping direct identifiers and using random alphanumeric codes), there is a small risk that public genomic repositories could be cross-referenced with commercial genealogy databases, leading to re-identification of you or your biological relatives. The repository uses secure firewalls and encryption to prevent such breaches.
Psychological Distress: Learning about genetic predispositions to untreatable or late-onset medical conditions (such as Huntington's disease or hereditary dementias) can cause significant anxiety, psychological distress, or family strain.

Return of Incidental and Actionable Findings

During genomic sequencing, researchers may identify 'incidental findings.' These are genetic variants unrelated to the primary study purpose but associated with other serious medical conditions. In accordance with the American College of Medical Genetics and Genomics (ACMG) guidelines, the study team monitors for highly actionable genetic variants (such as BRCA1/BRCA2 mutations for breast cancer risk or Lynch syndrome mutations). If an actionable variant is identified, the team will offer to disclose the results and provide access to a professional genetic counselor. You have the right to opt-in or opt-out of receiving these incidental findings in the options section below.

Data Sharing and Federal Repositories

To maximize the scientific value of this research, your de-identified genomic sequencing files and health information will be shared with national scientific databases, such as the National Institutes of Health (NIH) Database of Genotypes and Phenotypes (dbGaP). Access to dbGaP is restricted to approved scientific researchers who sign data-use agreements. Your name and direct identifiers will never be shared with these public repositories.

Specimen Withdrawal and Destruction Rules

You may change your mind and request the withdrawal of your specimens from the biobank at any time by contacting the Principal Investigator in writing. Upon receiving your written request, the biobank will locate and destroy any remaining physical biospecimens. However, any samples that have already been fully de-identified, analyzed, shared with federal databases, or used in scientific publications cannot be retrieved, recalled, or destroyed.

Genomic Research Opt-In Elections

[ ] I agree to the indefinite storage of my biological samples and genomic data in the biobank for future secondary research related to any medical condition.
[ ] I do NOT agree to biobanking for future secondary research. My samples must be destroyed upon completion of the primary study.
[ ] I agree to have the research team contact me in the future to return clinically actionable incidental genetic findings.
[ ] I do NOT wish to receive any incidental genetic findings from this study.

Participant Acknowledgment and Authorization

I confirm that I have read this informed consent form. The study team has answered all my questions. I voluntarily agree to participate in this genetic study, donate my biological specimens, and authorize the research use of my genomic data as described.

Signatures and Verification

Participant / LAR Signature
Relationship (if LAR)
Investigator Signature
Witness Signature (if required by IRB)
Date and Time of Consent
Document ID: CC-PENDING
CONSENTCOLLECT